Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1954 1
1955 1
1956 1
1957 1
1958 1
1959 4
1960 1
1961 10
1962 5
1965 18
1966 29
1967 46
1968 37
1969 58
1970 72
1971 77
1972 51
1973 38
1974 37
1975 25
1976 31
1977 18
1978 23
1979 26
1980 28
1981 24
1982 23
1983 31
1984 45
1985 53
1986 64
1987 90
1988 119
1989 117
1990 110
1991 175
1992 176
1993 205
1994 230
1995 261
1996 240
1997 256
1998 235
1999 310
2000 319
2001 425
2002 510
2003 585
2004 650
2005 793
2006 1074
2007 1251
2008 1419
2009 1615
2010 1751
2011 2057
2012 2018
2013 2038
2014 2121
2015 2011
2016 2217
2017 2642
2018 2701
2019 2916
2020 3243
2021 3137
2022 2545
2023 2148
2024 704

Text availability

Article attribute

Article type

Publication date

Search Results

40,296 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. André F, et al. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Lancet. 2023. PMID: 37086745 Clinical Trial.
Tezepelumab: First Approval.
Hoy SM. Hoy SM. Drugs. 2022 Mar;82(4):461-468. doi: 10.1007/s40265-022-01679-2. Drugs. 2022. PMID: 35184265 Review.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Teplizumab.
Beninger P. Beninger P. Clin Ther. 2023 Jul;45(7):684. doi: 10.1016/j.clinthera.2023.05.003. Epub 2023 May 29. Clin Ther. 2023. PMID: 37258327 No abstract available.
Tralokinumab-ldrm.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2022 Apr 1;79(8):616-617. doi: 10.1093/ajhp/zxac020. Am J Health Syst Pharm. 2022. PMID: 35267017 No abstract available.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. Paz-Ares LG, et al. J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12. J Thorac Oncol. 2022. PMID: 34648948 Free article. Clinical Trial.
40,296 results
You have reached the last available page of results. Please see the User Guide for more information.